Duncan Kennedy
Nessuna posizione attualmente
Patrimonio netto: 16 485 $ in data 31/03/2024
Profilo
Duncan Kennedy served as the Chief Financial Officer & Director at BTG Ltd.
from 2018 to 2019 and as the Chief Financial Officer & Executive Director at James Fisher & Sons Plc from 2021 to 2023.
Prior to these roles, he obtained an undergraduate degree from the University of Durham.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 31/12/2022 | 5 000 ( 0.01% ) | 16 485 $ | 31/03/2024 |
Precedenti posizioni note di Duncan Kennedy
| Società | Posizione | Fine |
|---|---|---|
| JAMES FISHER AND SONS PLC | Director of Finance/CFO | 01/12/2023 |
| BTG | Director of Finance/CFO | 31/12/2019 |
Formazione di Duncan Kennedy
| University of Durham | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| JAMES FISHER AND SONS PLC | Transportation |
| Aziende private | 1 |
|---|---|
BTG Ltd.
 BTG Ltd. Pharmaceuticals: MajorHealth Technology BTG Ltd. is a global healthcare company, which focuses on interventional medicine that can help physicians to treat patients through minimally invasive procedures. It operates through the following segments: Product, Licensing, and Other. The firm's products include CroFab, DigiFab, Voraxage. The company was founded on December 12, 1991 and is headquartered in Farnham, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Duncan Kennedy
